Beauty

Shiseido to sell Aupres subsidiary SLC to IDG-led consortium

Mira SolenNovember 19, 20265 min read4 views

At a glance

  • The Japanese group is divesting a long-established China business to focus resources on priority brands and higher-growth opportunities.
  • Shiseido has agreed to sell Shiseido Liyuan Cosmetics, which makes and sells Aupres in China, to an investor consortium led by IDG Capital, with closing expected between late 2026 and early 2027. The divestment is intended to concentrate resources on priority brands and higher-growth opportunities.
An unbranded skincare display and a glass-walled production area are linked by abstract document forms in cool daylight.

Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-headquartered private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Shiseido did not disclose the financial terms.

The sale is part of the Japanese cosmetics group's 2030 Medium-Term Strategy, under which it aims to improve profitability and capital efficiency. Shiseido said it wants to drive sustainable growth and strengthen its competitiveness in China by directing management resources to areas where it 'enjoys the greatest competitive advantage.' The company described the divested business as one that needs continued investment in product innovation and digital capabilities. By exiting it, Shiseido intends to concentrate on priority brands and higher-growth opportunities.

Ownership and handover

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. The company has sold the C-beauty brand Aupres since 1994. With the existing joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan's 35% stake, giving it full ownership ahead of the sale.

Under the transaction, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles. A limited partnership enterprise set up mainly by SLC's new management team will hold the remaining 5%. The deal includes SLC's Beijing factory and production equipment. Shiseido said it believes independent operation under IDG will support SLC's sustainable growth and brand value.

To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. Shiseido said the arrangements are meant to maintain SLC's innovation capabilities, product quality and business continuity.

China priorities

Shiseido described China as a strategically important market and an attractive, dynamic market where the competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants. The company's stated approach is to keep focusing on areas of competitive strength rather than retaining a business that requires sustained investment.

The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. On the back of those results, Shiseido raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million).

The transaction remains subject to approvals, and its completion will transfer a long-established Chinese cosmetics business to new owners.

Reported by Mira Solen, Skincare Formulation Analyst.